Zandelisib

LITS Is the First and Only US Publicly Traded Company to Gain Institutional Exposure to LTC, Holding 929,548 LTC TokensSAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ: LITS) (“Lite Strategy” or “LITS”) today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate events related to the Company’s digital asset treasury strategy as well as its pharmaceutical operations. “Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus,” Board Member Charlie Lee said. “We recently celebrated Litecoin’s 14th anniversary and its unblemished track record of reliability and uptime. LITS provides investors the only US publicly traded company to gain institutional exposure to Litecoin, both for portfolio diversification and long-term value.” “Fiscal year 2026 will showcase the results of the transformative steps taken by Lite Strategy. Since the start of our strategic alternatives process in fiscal year 2025, we have prioritized maximizing the value of our assets for stockholders. Starting with the successful sale of our clinical asset, ME-344 (now known as WE-868), currently being developed for adults with obesity at Aardvark Therapeutics, and continuing through the close of our $100 million PIPE offering in July 2025 that kicked off our Litecoin digital asset treasury strategy in the first quarter of this fiscal year,” said Jay File, CEO, CFO. First Quarter Fiscal Year 2026 and Recent Highlights Raised $100 million in aggregate gross proceeds, commencing the Company’s long-term strategic plan with Litecoin as a digital asset treasury reserve asset.Officially became the first U.S.-listed public company to adopt Litecoin as a primary reserve asset with the acquisition of 929,548 Litecoin (LTC) tokens, implementing a new strategy built on a digital asset infrastructure and long-term capital innovation.Entered into a strategic partnership with GSR, a leading crypto investment firm, to guide LITS’ digital asset treasury strategy, ensuring robust governance, execution, and market expertise.Brought on world-class board members, Charlie Lee, creator of Litecoin, and Joshua Riezman, U.S. Chief Strategy Officer at GSR.Rebranded from MEI Pharma to Lite Strategy, including changing the Company’s corporate name and NASDAQ Stock Market ticker from MEIP to LITS, and unveiling a new corporate logo and website. The rebranding underscores the Company’s commitment to building a long-term corporate strategy around LTC as its primary reserve asset.In October announced a $25 million share repurchase program, advancing LITS from the initial phase of Litecoin accumulation to active capital market operations and allowing LITS to leverage our nearly 1 million LTC treasury - a key differential from passive investment structures like exchange-traded funds. “As we progress further into fiscal year 2026, we continue to evaluate our clinical assets including the commencement of pre-clinical studies with voruciclib in non-oncology disease indications for potential licensing to third parties, and pursuing licensing or sale opportunities with zandelisib,” said Jay File. “We will consider opportunities to deploy our recently announced $25 million stock buyback program until our discount to NAV is normalized. We look forward to executing on all our corporate objectives as we progress through fiscal year 2026.” As of September 30, 2025, the Company had $12.21 million in working capital with no outstanding debt. To learn more about Lite Strategy, visit the Company’s homepage at https://litestrategy.com. To learn more about Litecoin and its role in Lite Strategy’s treasury, visit our About Litecoin page at https://litestrategy.com/about-litecoin/. To learn more about the transaction with Aardvark, read our Form 8-K filing at https://investor.meipharma.com/sec-filings/sec-filing/8-k/0000950170-24-117406. For current holdings and related Company metrics, visit Lite Strategy’s dashboard at https://litestrategy.com/dashboard/. About Lite Strategy, Inc. (LITS) Lite Strategy, Inc. (NASDAQ: LITS) is the first U.S. publicly traded company to adopt Litecoin as its primary reserve asset. Formerly MEI Pharma, the Company has expanded its business model beyond its portfolio of drug candidates to focus on pioneering institutional-grade digital asset treasury strategies, in partnership with leading innovators across blockchain, finance, and technology. Forward-Looking Statements Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding our future actions, prospective products and activities, future performance or results. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, risk relating to being able to repurchase our shares in the market on attractive e terms or at all, maintaining our current listing on Nasdaq, our ability to retain and attract senior management and other key employees, fluctuations in the market price of LTC and any associated impairment charges that we may incur as a result of a decrease in the market price of LTC below the value at which LTC is carried on our balance sheet, changes in the accounting treatment relating to our LTC holdings, our ability to achieve profitable operations, government regulation of cryptocurrencies and online betting, changes in securities laws or regulations, customer acceptance of new products and services including our LTC treasury strategy, our ability to utilize our repurchase program, the demand for our products and our customers’ economic condition, the impact of competitive products and pricing, our proprietary rights, general economic conditions and other risk factors detailed in our annual report and other filings with the SEC. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. Contacts: Justin J. FileCEO, CFO 858-369-7199investor@litestrategy.comSource: Lite Strategy, Inc.

近日（7月22日，8：30），MEI Pharma宣布，该公司已经进入战略选择评估阶段以实现股东资产最大化，未来面临的选择包括破产结算或者资产出售，公司将停止一切临床开发，只保留部分药物的非临床合作项目，公司CEO David Urso，CMO Richard Ghalie，董事会主席Charles Baltic将要离职，裁员将很快开始。 这也标志着这家成立20多年的Biotech正式步入倒计时。 有趣的是，在宣布该消息后，该公司股价非但没有下跌，反而上涨。7月22日中午一度达到超过35%的涨幅，截止22日收盘，股价比前一个交易日上涨约21%。 处境尴尬的MEI Pharma MEI Pharma最开始叫做Marshall Edwards Inc.，当时开发的核心管线是一种细胞凋亡药物phenoxodiol，可以使得癌细胞对凋亡敏感。 2012年转型成MEI Pharma（实际上就是前者名称的缩写），开始寻求收购有前途的癌症药物。 转型后这家公司手中有三条管线，细胞周期蛋白依赖性激酶9（CDK9）抑制剂Voruciclib，小分子线粒体抑制剂ME-344，以及PI3Kδ抑制剂Zandelisib。其中Zandelisib是这家公司大力推广的核心管线。 2022年，MEI Pharma寄希望于Zandelisib在滤泡性淋巴（FL）适应症上获得加速批准，也确实在TIDAL试验中取得了较高的客观缓解率（ORR）。 然而，由于数据尚不足够成熟，且缺乏随机对照试验的支持，FDA在审查后拒绝了Zandelisib的上市申请。MEI Pharma随后决定停止在日本之外该药物的开发，仅由其合作伙伴Kyowa Kirin（协和麒麟）推进日本境内的II期试验。 实际上FDA的决策反应了当时对于PI3Kδ抑制剂的态度。 之前就有多家公司在PI3Kδ抑制剂中获得了不错的ORR，但是验证性临床最终失败，吉利德的Idelalisib，Incyte的Parsaclisib都是加速批准后，自愿撤市的前车之鉴。 因此当FDA关闭加速批准的窗口后，MEI Pharma的处境相当尴尬。 寻求合并遭到MEI拒绝 在2023年时，处境同样堪忧的Infinity Pharmaceuticals（成立于1995年）找到了MEI Pharma试图合并。 有趣的是，Infinity Pharmaceuticals这家公司的核心管线是PI3Kγ抑制剂eganelisib，那时候这家公司已经为了核心管线耗尽了自己的现金储备，Infinity的管理层在去年3月份提到，合并是这家公司免于破产的唯一方法。 根据合并协议条款，Infinity将成为MEI的全资子公司，MEI的股东将拥有合并后公司约58%的股份，而其余股份将由Infinity的股东持有。 合并以后的公司会在账上拥有1亿美元现金，同时获得eganelisib，ME-344，Voruciclib三条管线组合。 MEI似乎在最开始同意了收购，也确实看到了收购可能带来的好处，但是到了最关键的投票环节，MEI的股东对合并提出了异议。 Cable Car Capital和Anson Advisors这两家公司共拥有MEI 8%的股份，在最关键的时刻，他们牵头的一个小组给出了8美元更高的报价，提出可以用8美元收购MEI，而当时MEI的股价是7.2美元。 虽然MEI的管理层也声称8美元的报价大大低估了公司的资产，认为这太少了，但是关键的投票环境，票型让合并彻底失败——以恰好51%的票型反对该交易。 Infinity的管理层也并没有食言，失去了资金来源的Infinity Pharmaceuticals很快就在2023年下半年破产，而现在破产的轮盘转到了MEI Pharma的头上。 实际上MEI Pharma的财务状况也不支持这家公司继续花钱下去了，该公司账上只剩下5660万美元，账上现金将不支持这家公司再运营一年了。在资金难融的背景下，这家老企业寻求破产或出售反而不一定是坏事。 本周好文推荐 如需转载请联系佰傲谷并在醒目位置注明出处 · · · · · · · ·